Invention Grant
- Patent Title: Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
- Patent Title (中): 哒嗪基大环丙型肝炎丝氨酸蛋白酶抑制剂
-
Application No.: US11832893Application Date: 2007-08-02
-
Publication No.: US07718612B2Publication Date: 2010-05-18
- Inventor: Joel D. Moore , Datong Tang , Yat Sun Or , Zhe Wang
- Applicant: Joel D. Moore , Datong Tang , Yat Sun Or , Zhe Wang
- Applicant Address: US MA Watertown
- Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee: Enanta Pharmaceuticals, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Elmore Patent Law Group, P.C.
- Agent Roy P. Issac; Carolyn S. Elmore
- Main IPC: A61K38/12
- IPC: A61K38/12 ; C07K5/12
Abstract:
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
Public/Granted literature
- US20090035272A1 Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors Public/Granted day:2009-02-05
Information query
IPC分类:
